Results 141 to 150 of about 2,077 (188)
Ospemifene in the Treatment of Vulvovaginal Atrophy
Annals of Pharmacotherapy, 2014 Objective: To review the pharmacology, efficacy, and safety of ospemifene in the management of dyspareunia. Data Sources: Literature was sought using PubMed (1966-January 2014) and EMBASE (1973-January 2014). Search terms included ospemifene, FC-1271a, dyspareunia, vulvovaginal atrophy, and vaginal atrophy.
Kylie N, Barnes +3 more
openaire +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Current treatment options for vulvovaginal atrophy
Expert Review of Obstetrics and Gynecology, 2011Vulvovaginal atrophy (VVA), a condition associated with declining estrogen levels, is commonly seen in postmenopausal women. VVA is marked by vaginal dryness, itching, dyspareunia and incontinence, which can contribute to diminishing quality of life for millions of postmenopausal women worldwide.
Michael W Degregorio
exaly +2 more sources
Injection Treatments for Vulvovaginal Atrophy of Menopause: A Systematic Review
Aesthetic Plastic Surgery, 2023 Injection treatments have been proposed as novel treatment options for Vulvovaginal Atrophy of Menopause (VVA) also known as Genitourinary Syndrome of Menopause (GSM). However, to date data about these treatments are poor.To assess all available injection treatments for VVA.A systematic review was performed by searching five electronic databases for ...
Moccia, Felice +5 more
openaire +5 more sources
Climacteric, 2018 The primary objective of the European Vulvovaginal Epidemiological Survey (EVES) was to assess, at a country level, the prevalence of postmenopausal women with vulvovaginal atrophy (VVA) confirmed by gynecological clinical assessment among all ...
Santiago Palacios +2 more
exaly +3 more sources
Sequential treatment in vulvovaginal atrophy
Climacteric, 2023Vulvovaginal atrophy (VVA) is a chronic and progressive disease that affects sexuality and quality of life. VVA is preventable and treatable, but requires long-term and often sequential treatment. Sequential treatment consists of designing a strategy that uses one or more medications for a long enough time to achieve the desired benefits with minimal ...
openaire +2 more sources
Vulvovaginal atrophy – a tale of neglect
Climacteric, 2014The impact of vulvovaginal atrophy (VVA) on quality of life continues to be underestimated according to an expert review published in this issue of Climacteric1.
Nick, Panay, Anna, Fenton
openaire +2 more sources
Ospemifene, vulvovaginal atrophy, and breast cancer
Maturitas, 2013The incidence and severity of vulvovaginal atrophy (VVA) in postmenopausal breast cancer patients has a significant impact on quality of life. While the etiology of VVA is primarily related to low estrogen levels seen in menopause, women with breast cancer have an added risk of VVA induced by a combination of chemotherapy, hormonal therapy, and ...
Gregory T, Wurz +2 more
openaire +2 more sources
Vulvovaginal atrophy in women after cancer
Climacteric, 2019The number of women surviving longer after a cancer diagnosis is increasing. This means that more awareness regarding their health is required. This review will focus on vulvovaginal atrophy (VVA)/genitourinary syndrome of menopause, one of the most distressing adverse iatrogenic effects of the menopause, secondary to cancer therapies.
P, Cox, N, Panay
openaire +2 more sources